

4-4-2017

Chemical and Physical Priming of Human Mesenchymal Stem Cells to Alter Nonviral Gene Delivery Outcomes

Tyler Kozisek
tkozi1992@gmail.com

Andrew Hamann
University of Nebraska-Lincoln, ahamann2@unl.edu

Amy Mantz
University of Nebraska-Lincoln, amy.mantz@gmail.com

Mathias Schubert
University of Nebraska - Lincoln, mschubert4@unl.edu

Eva Schubert
University of Nebraska-Lincoln, efranke3@unl.edu

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.unl.edu/biosysengdiss>

 Part of the [Biological Engineering Commons](#), [Biomechanics and Biotransport Commons](#), [Molecular, Cellular, and Tissue Engineering Commons](#), and the [Other Biomedical Engineering and Bioengineering Commons](#)

Kozisek, Tyler; Hamann, Andrew; Mantz, Amy; Schubert, Mathias; Schubert, Eva; and Pannier, Angela K., "Chemical and Physical Priming of Human Mesenchymal Stem Cells to Alter Nonviral Gene Delivery Outcomes" (2017). *Biological Systems Engineering--Dissertations, Theses, and Student Research*. 71.
<https://digitalcommons.unl.edu/biosysengdiss/71>

This Article is brought to you for free and open access by the Biological Systems Engineering at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biological Systems Engineering--Dissertations, Theses, and Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Tyler Kozisek, Andrew Hamann, Amy Mantz, Mathias Schubert, Eva Schubert, and Angela K. Pannier

Background and Hypothesis

Human Mesenchymal Stem Cells: Human mesenchymal stem cells (hMSCs) are a multipotent cell, meaning they are able to differentiate into a more mature cell type, such as osteocytes, chondrocytes, and adipocytes, that are found in numerous tissues in the human body, such as bone marrow, fat, and muscle. Since hMSCs can be derived from adult human tissues, they do not have the same ethical concern associated with them as other stem cells, such as embryonic stem cells. Due to hMSCs multipotency and ease of obtaining, they have become one of the most widely researched stem cell types in areas such as tissue engineering and regenerative medicine, targeted delivery of drugs/secretion of therapeutic proteins, and cancer therapy¹.

Nonviral Gene Delivery: Nonviral gene delivery is the transfer of exogenous genetic material (e.g. plasmid DNA, siRNA) to cells using a nonviral vector, typically a cationic lipid or polymer. While nonviral delivery systems are considered safer than viral delivery systems, nonviral gene delivery suffers from low transfection efficiencies, especially in hMSCs, which limits its therapeutic potential. Our lab has previously shown that priming hMSCs with the glucocorticoid (GC) dexamethasone (DEX) 0-30 minutes prior to transfection can increase transgene expression by as much as 13 fold in hMSCs derived from numerous donors and tissues¹.




Figure 1: (A,C) Enhanced transgene expression in BMSCs from DEX. (B) Molecular structure of dexamethasone.

Hypothesis: We hypothesize that **physical** and **chemical priming** of hMSCs prior to and during **nonviral gene delivery** can elicit a **tailored** response (i.e. activation of signaling pathways, increased proliferation, integrin clustering) that can alter the **transfection outcomes** in hMSCs.

Methods

Glancing Angle Deposition (GLAD)²




Figure 2: (A) Physical priming of hMSCs was achieved by culturing on titanium (Ti) sculptured thin films (STFs) formed by GLAD. (B) STFs used were slanted columnar thin films (SCTFs), vertical columnar thin films (VCTF), pre-nucleated slanted columnar thin films (pnSCTFs), and flat Ti. Chemical priming of hMSCs was achieved by addition of DEX to the culture media.

Transfection of hMSCs

All transfection studies were performed using reporter plasmid encoding for a green fluorescent and luciferase fusion protein driven by a cytomegalovirus (CMV) promoter, and complexed with Lipofectamine (Invitrogen) lipid transfection reagents. Luciferase assay (Promega) was used to quantify transfection in relative light units, normalized to total protein. Adipose derived mesenchymal stem cells (AMSCs) and bone marrow derived mesenchymal stem cells (BMSCs) between passages 2 and 7 were used in all studies.

Results

AMSCs Cultured on SCTFs Show Increased Transgene Expression for Bolus Delivery of Lipoplexes





Figure 3: Schematic for bolus delivery of lipoplexes to hMSCs cultured on STFs.

Figure 4: (A) A 3 fold increase in transgene expression, compared to both polystyrene (PS) and flat Ti, is seen for AMSCs cultured on SCTFs prior to bolus delivery of lipoplexes. (B) BMSCs do not see the same increase, suggesting physical cues from the substrate are interpreted differently by each stem cell type.

Figure 5: (A,B) Although transgene expression is increased for all STFs with the addition of DEX, (A) a synergistic effect is not seen when DEX is added to AMSCs cultured on SCTFs



Substrate Mediated Delivery (SMD) Shows Increase in Fold Change (DEX+/DEX-) for hMSCs cultured on SCTFs




Figure 6: Schematic for SMD of lipoplexes to hMSCs cultured on STFs.




Figure 8: (A) Both physical and chemical priming of AMSCs lead to a significantly higher fold increase (DEX+/DEX-) in transgene expression for SMD of lipoplexes. BMSCs also show an increase in transgene expression for SMD of lipoplexes.




Figure 7: Different combinations of DNA concentration (0.05-1.5 μg/well) and DNA to lipid ratios (1:1, 1:2, 1:3) were tested to optimize SMD of lipoplexes to hMSCs. The graph demonstrates that lower DNA concentration paired with lower DNA to lipid ratios work best for SMD of lipoplexes to hMSCs.

Conclusions

- SCTFs increase transgene expression in AMSCs receiving bolus delivery of lipoplexes.
 - Similar results are not seen in BMSCs cultured on SCTFs, suggesting physical cues are interpreted differently by hMSCs derived from different tissues.
- DEX increases transgene expression in AMSCs cultured on STFs, but does not add to increase seen in SCTF cultured AMSCs.
- SMD requires ¼ of the plasmid DNA and ½ of the complexing agent compared to bolus.
- AMSCs cultured on SCTFs show a significantly higher fold increase (DEX+/DEX-) in transgene expression for lipoplexes delivered via SMD.

Future Directions

- Fully characterize genotype of hMSCs cultured on STFs to identify key genes and their effects on transfection of hMSCs.
- Use photolithography techniques to create substrates with nano- and micro-scale features.
- Optimize lipoplex loading onto STFs and DEX timing for SMD studies.
- Research other areas of interest for STFs, such as hMSCs differentiation, drug loading, and bactericidal properties.

Acknowledgements and Funding

Pannier Lab

- Sarah Plautz, Eric Farris, Amy Mantz, Andrew Hamann, Albert Nguyen, Anna Lampe, Tyler Kozisek, Jordan Verplank, Freshta Baher, Austin Helmink, Alec McCarthy, Bailey Eddy, Matt Boren, and Connor States

Collaborators/Core Facilities

- Center for Nanohybrid Functional Material

Funding

- J.A. Woollam Company
- NSF Career